Emerging data suggests a compelling alliance between the GLP-1/GIP receptor agonist, retatrutide , and NAD+ . While this medication and this drug have demonstrated remarkable success in addressing insulin resistance and facilitating weight loss , findings now points to that enhancing metabolic performance with NAD+ could further enhance {metabol… Read More